
Guidance for Industry

Drug Interaction Studies — Study Design, Data Analysis, and Implications for Dosing and Labeling

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Shiew-Mei Huang, 301-796-1541, or (CBER) Toni Stifano, 301-827-6190.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**September 2006
Clinical Pharmacology**

Guidance for Industry

Drug Interaction Studies — Study Design, Data Analysis, and Implications for Dosing and Labeling

Additional copies are available from:

*Office of Training and Communications
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
<http://www.fda.gov/cder/guidance/index.htm>*

or

*Office of Communication, Training and
Manufacturers Assistance, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
<http://www.fda.gov/cber/guidelines.htm>*

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**September 2006
Clinical Pharmacology**

G:\6695dft.doc
09/08/06

TABLE OF CONTENTS

I. INTRODUCTION.....	1
II. BACKGROUND	2
A. METABOLISM	2
B. DRUG-DRUG INTERACTIONS	2
III. GENERAL STRATEGIES	4
A. IN VITRO STUDIES.....	4
B. SPECIFIC IN VIVO CLINICAL INVESTIGATIONS.....	5
C. POPULATION PHARMACOKINETIC SCREENS	6
IV. DESIGN OF IN VIVO DRUG-DRUG INTERACTION STUDIES	6
A. STUDY DESIGN.....	6
B. STUDY POPULATION.....	8
C. CHOICE OF SUBSTRATE AND INTERACTING DRUGS	8
D. ROUTE OF ADMINISTRATION	12
E. DOSE SELECTION	12
F. ENDPOINTS.....	13
G. SAMPLE SIZE AND STATISTICAL CONSIDERATIONS	14
V. LABELING IMPLICATIONS	15
APPENDIX A TABLES.....	17
APPENDIX B FIGURES.....	24
APPENDIX C-1 IN VITRO DRUG METABOLIZING ENZYME IDENTIFICATION	25
APPENDIX C-2 IN VITRO EVALUATION OF CYP INHIBITORS.....	31
APPENDIX C-3 IN VITRO EVALUATION OF CYP INDUCTION.....	35
APPENDIX D IN VITRO EVALUATION OF P-GLYCOPROTEIN (P-GP, MDR1) SUBSTRATES AND INHIBITORS.....	38
REFERENCES	51

G:\6695dft.doc
09/08/06

Contains Nonbinding Recommendations

Draft – Not for Implementation
Guidance for Industry¹

Drug Interaction Studies — Study Design, Data Analysis, and
Implications for Dosing and Labeling

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance provides recommendations for sponsors of new drug applications (NDAs) and biologics license applications (BLAs) for therapeutic biologics² who are performing in vitro and in vivo drug metabolism, drug transport, and drug-drug interaction studies. The guidance reflects the Agency's current view that the metabolism of an investigational new drug should be defined during drug development and that its interactions with other drugs should be explored as part of an adequate assessment of its safety and effectiveness. For drug-drug interactions, the approaches considered in the guidance are offered with the understanding that the relevance of a particular study depends on the characteristics and proposed indication of the drug under development. Furthermore, not every drug-drug interaction is metabolism-based, but may arise from changes in pharmacokinetics caused by absorption, distribution, and excretion interactions. Drug-drug interactions related to transporters are being documented with increasing frequency and are important to consider in drug development. Although less well studied, drug-drug interactions may alter pharmacokinetic/pharmacodynamic (PK/PD) relationships. These important areas are not considered in detail in this guidance.

Discussion of metabolic and other types of drug-drug interactions is also provided in other guidances, including the International Conference on Harmonization (ICH) *E7 Studies in Support of Special Populations: Geriatrics*, and *E3 Structure and Content of Clinical Study Reports*, and FDA guidances for industry on *Studying Drugs Likely to be Used in the Elderly* and *Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs*.

¹ This guidance has been prepared by the Drug-Drug Interaction Working Group in the Clinical Pharmacology Section of the Medical Policy Coordinating Committee in the Center for Drug Evaluation and Research, with input from the Center for Biologics Evaluation and Research, at the Food and Drug Administration.

² For more information on what constitutes a therapeutic biologic product, please see Internet site <http://www.fda.gov/cder/biologics/qa.htm>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

40
41 FDA's guidance documents, including this guidance, do not establish legally enforceable
42 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and
43 should be viewed only as recommendations, unless specific regulatory or statutory
44 requirements are cited. The use of the word *should* in Agency guidances means that
45 something is suggested or recommended, but not required.

46
47

48 **II. BACKGROUND**

49

50 **A. Metabolism**

51

52 The desirable and undesirable effects of a drug arising from its concentrations at the sites of
53 action are usually related either to the amount administered (dose) or to the resulting blood
54 concentrations, which are affected by its absorption, distribution, metabolism, and/or
55 excretion. Elimination of a drug or its metabolites occurs either by metabolism, usually by
56 the liver or gut mucosa, or by excretion, usually by the kidneys and liver. In addition,
57 protein therapeutics may be eliminated through a specific interaction with cell surface
58 receptors, followed by internalization and lysosomal degradation within the target cell.
59 Hepatic elimination occurs primarily by the cytochrome P450 family (CYP) of enzymes
60 located in the hepatic endoplasmic reticulum, but may also occur by non-P450 enzyme
61 systems, such as N-acetyl and glucuronosyl transferases. Many factors can alter hepatic and
62 intestinal drug metabolism, including the presence or absence of disease and/or concomitant
63 medications, or even some foods, such as grapefruit juice. While most of these factors are
64 usually relatively stable over time, concomitant medications can alter metabolism abruptly
65 and are of particular concern. The influence of concomitant medications on hepatic and
66 intestinal metabolism becomes more complicated when a drug, including a prodrug, is
67 metabolized to one or more active metabolites. In this case, the safety and efficacy of the
68 drug/prodrug are determined not only by exposure to the parent drug but by exposure to the
69 active metabolites, which in turn is related to their formation, distribution, and elimination.
70 Therefore, adequate assessment of the safety and effectiveness of a drug includes a
71 description of its metabolism and the contribution of metabolism to overall elimination. For
72 this reason, the development of sensitive and specific assays for a drug and its important
73 metabolites is critical to the study of metabolism and drug-drug interactions.

74

75 **B. Drug-Drug Interactions**

76

77 *1. Metabolism-Based Drug-Drug Interactions*

78

79 Many metabolic routes of elimination, including most of those occurring through the
80 P450 family of enzymes, can be inhibited or induced by concomitant drug treatment.
81 Observed changes arising from metabolic drug-drug interactions can be substantial —
82 an order of magnitude or more decrease or increase in the blood and tissue
83 concentrations of a drug or metabolite — and can include formation of toxic and/or

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.